Oncology Xagena
The results of several clinical studies of Cetuximab ( Erbitux ) have been presented at the American Society of Clinical Oncology ( ASCO ) 41st Annual Meeting. Irinotecan-refractory metastatic co ...
A new treatment for pancreatic cancer developed by researchers of Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center substantially reduces the size of tumors and lowers the risk of loca ...
Patients treated for locally advanced head and neck cancer may respond better to treatment with the addition of Cetuximab ( Erbitux ) to chemotherapy, according to a phase II study. In the study, ...
European Researchers have found that metastatic colorectal cancer patients with a mutation in the BRAF gene do not respond to anti-EGFR therapy with Cetuximab ( Erbitux ) and Panitumumab ( Vectibix ...
Adding Cetuximab ( Erbitux ) to radiation therapy prolongs survival in patients with locally advanced head and neck cancer compared with radiotherapy alone, and this improvement persists for up to 5 y ...
Adding Cetuximab ( Erbitux ) to neoadjuvant chemotherapy can shrink tumours leading to increased potentially curative surgery in patients who have colorectal cancer with inoperable metastatic liver le ...
Results from a clinical trial conducted in Shanghai, China, have indicated that adding Cetuximab ( Erbitux ) to standard chemotherapy enables some patients with otherwise inoperable liver metastases d ...
The FIRE-3 study has compared the two epidermal growth factor receptor ( EGFR ) antibodies, on top of chemotherapy, in the first-line treatment of metastatic colorectal cancer. A preplanned analysis ...
Colorectal cancer is one of the most common human malignancies with greater than 300,000 cases both in the United States and in the European Union each year. In the past decade, survival of metastat ...
In patients with KRAS, wild-type metastatic colorectal cancer ( mCRC ) a head to head comparison of anti-EGFR- and anti-VEGF-directed first-line therapy has not been reported with regard to the FOLFIR ...
Cetuximab ( Erbitux ) is efficient in advanced colorectal cancer ( CRC ). Researchers previously showed that KRAS mutations were associated with resistance to Cetuximab in 30 CRC patients. The aim ...
HPV initiated ( HPV+ ) squamous cell carcinoma of oropharynx ( SCCOP ) has a unique epidemiology, biology, and genetic profile compared to HPV- disease and is associated with excellent outcomes after ...
The anti-EGFR monoclonal antibodies Panitumumab ( Vectibix ) and Cetuximab ( Erbitux ) are effective in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. A st ...
Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of Oxaliplatin ( Eloxatin ) and Fluorouracil ch ...
Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of Oxaliplatin ( Eloxatin ) and Fluorouracil ( ...
